Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions☆

[1]  Y. Barenholz,et al.  Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine) , 2022, Journal of Controlled Release.

[2]  P. Nilsson,et al.  Pitfalls in complement analysis: A systematic literature review of assessing complement activation , 2022, Frontiers in Immunology.

[3]  D. Simberg,et al.  Nanometer- and angstrom-scale characteristics that modulate complement responses to nanoparticles , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[4]  L. Calzolai,et al.  Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration , 2022, International journal of molecular sciences.

[5]  E. Lavik,et al.  PEGylated Polyester Nanoparticles Trigger Adverse Events in a Large Animal Model of Trauma and in Naı̈ve Animals: Understanding Cytokine and Cellular Correlations with These Events. , 2022, ACS nano.

[6]  Z. S. Farhangrazi,et al.  A brief history of long circulating nanoparticles. , 2022, Advanced drug delivery reviews.

[7]  D. Simberg,et al.  Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology , 2022, Nano Today.

[8]  Krishna M. G. Mallela,et al.  Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on “Pseudovirus-like” Nanoparticles , 2022, ACS nano.

[9]  V. Simon,et al.  mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations , 2022, Vaccine.

[10]  M. Kiss,et al.  The multifaceted impact of complement on atherosclerosis. , 2022, Atherosclerosis.

[11]  I. Mellman,et al.  IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines , 2022, Nature Immunology.

[12]  V. Muzykantov,et al.  Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles , 2021, Advanced materials.

[13]  B. Igyártó,et al.  The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory , 2021, iScience.

[14]  A. Neves,et al.  Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? , 2021, International journal of molecular sciences.

[15]  E. Lavik,et al.  Engineering PEGylated Polyester Nanoparticles to Reduce Complement-Mediated Infusion Reaction. , 2021, Bioconjugate chemistry.

[16]  E. Groman,et al.  Complement opsonization of nanoparticles: Differences between humans and preclinical species. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[17]  T. Cheng,et al.  Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. , 2021, ACS nano.

[18]  D. Simberg,et al.  Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking , 2021, Nature Communications.

[19]  Joseph C. Sun,et al.  Natural Killer Cells: From Innate to Adaptive Features. , 2021, Annual review of immunology.

[20]  S. Mitragotri,et al.  Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers. , 2021, Annual review of biomedical engineering.

[21]  Chunye Zhang,et al.  Function of Macrophages in Disease: Current Understanding on Molecular Mechanisms , 2021, Frontiers in Immunology.

[22]  V. Ferreira,et al.  Hijacking Factor H for Complement Immune Evasion , 2021, Frontiers in Immunology.

[23]  S. Moghimi.  Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines , 2021, Molecular Therapy.

[24]  Md. Rakibul Islam,et al.  Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine , 2021, Frontiers in Immunology.

[25]  Laura F. Dagley,et al.  Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood. , 2020, ACS nano.

[26]  H. Andersen,et al.  A structurally diverse library of glycerol monooleate/oleic acid non-lamellar liquid crystalline nanodispersions stabilized with nonionic methoxypoly(ethylene glycol) (mPEG)-lipids showing variable complement activation properties. , 2020, Journal of colloid and interface science.

[27]  Joshua A. Jackman,et al.  Cloaking Silica Nanoparticles with Functional Protein Coatings for Reduced Complement Activation and Cellular Uptake. , 2020, ACS nano.

[28]  L. Gershwin,et al.  A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics , 2020, Clinical Reviews in Allergy & Immunology.

[29]  S. Moghimi,et al.  A rally for brain targeting: the advent of a new era. , 2020, Therapeutic delivery.

[30]  D. Simberg,et al.  Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities. , 2020, Advanced drug delivery reviews.

[31]  S. Doak,et al.  Nanomaterials and innate immunity: A perspective of the current status in nanosafety. , 2020, Chemical research in toxicology.

[32]  P. Decuzzi,et al.  Overcoming Nanoparticle-Mediated Complement Activation by Surface PEG-Pairing. , 2020, Nano letters.

[33]  T. Cheng,et al.  Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex. , 2020, ACS nano.

[34]  R. Harrison,et al.  Complement Receptor-Mediated Phagocytosis Induces Proinflammatory Cytokine Production in Murine Macrophages , 2020, Frontiers in Immunology.

[35]  John D Lambris,et al.  Therapeutic targeting of the complement system , 2019, Nature Reviews Drug Discovery.

[36]  E. Izquierdo,et al.  Targeting Macrophages: Friends or Foes in Disease? , 2019, Front. Pharmacol..

[37]  Lin-Ping Wu,et al.  Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide , 2019, Nature Communications.

[38]  E. Holland,et al.  Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers , 2019, Nature Communications.

[39]  S. Dzik.  Complement and Coagulation: Cross Talk Through Time. , 2019, Transfusion medicine reviews.

[40]  I. Screpanti,et al.  Interplay of protein corona and immune cells controls blood residency of liposomes , 2019, Nature Communications.

[41]  M. Alexander,et al.  The role of macrophages in the resolution of inflammation. , 2019, The Journal of clinical investigation.

[42]  P. Parren,et al.  Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces. , 2019, Nano letters.

[43]  E. Groman,et al.  Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[44]  S. Krol,et al.  Human serum albumin nanoparticles loaded with phthalocyanine dyes for potential use in photodynamic therapy for atherosclerotic plaques , 2019, Precision Nanomedicine.

[45]  D. Simberg,et al.  The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[46]  D. Sexton,et al.  Ficolins and the Recognition of Pathogenic Microorganisms: An Overview of the Innate Immune Response and Contribution of Single Nucleotide Polymorphisms , 2019, Journal of immunology research.

[47]  Seyed Moein Moghimi,et al.  Immunoglobulin deposition on biomolecule corona determines complement opsonisation efficiency of preclinical and clinical nanoparticles , 2018, Nature Nanotechnology.

[48]  William C Zamboni,et al.  Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations. , 2018, Advanced drug delivery reviews.

[49]  G. Arrigoni,et al.  C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes. , 2018, ACS nano.

[50]  D. Simberg,et al.  Translational gaps in animal models of human infusion reactions to nanomedicines. , 2018, Nanomedicine.

[51]  J. Szebeni,et al.  A porcine model of complement activation-related pseudoallergy to nano-pharmaceuticals: Pros and cons of translation to a preclinical safety test , 2018 .

[52]  J. Köhler,et al.  Interaction of the Human Contact System with Pathogens—An Update , 2018, Front. Immunol..

[53]  James Chen Yong Kah,et al.  Complement Activation by PEGylated Gold Nanoparticles. , 2018, Bioconjugate chemistry.

[54]  James Chen Yong Kah,et al.  Complement activation by gold nanoparticles passivated with polyelectrolyte ligands , 2018, RSC advances.

[55]  S. Moghimi.  Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. , 2017, Drug discovery today.

[56]  John D Lambris,et al.  The renaissance of complement therapeutics , 2018, Nature Reviews Nephrology.

[57]  S. Lorkowski,et al.  Kallikrein Cleaves C3 and Activates Complement , 2017, Journal of Innate Immunity.

[58]  Bengt Fadeel,et al.  Nanoparticles and innate immunity: new perspectives on host defence. , 2017, Seminars in immunology.

[59]  Christine Vauthier,et al.  Tuning complement activation and pathway through controlled molecular architecture of dextran chains in nanoparticle corona. , 2017, International journal of pharmaceutics.

[60]  T. Skotland.  Injection of nanoparticles into cloven-hoof animals: Asking for trouble , 2017, Theranostics.

[61]  D. Simberg,et al.  Interaction of extremophilic archaeal viruses with human and mouse complement system and viral biodistribution in mice. , 2017, Molecular immunology.

[62]  S M Moghimi,et al.  Complement activation turnover on surfaces of nanoparticles. , 2017, Nano today.

[63]  Guan Wang,et al.  Generation of complement protein C3 deficient pigs by CRISPR/Cas9-mediated gene targeting , 2017, Scientific Reports.

[64]  Samir Mitragotri,et al.  Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. , 2017, Nature nanotechnology.

[65]  S. Gordon,et al.  Tissue macrophages: heterogeneity and functions , 2017, BMC Biology.

[66]  Seyed Moein Moghimi,et al.  Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. , 2017, Nature nanotechnology.

[67]  T. Park,et al.  Diverse Applications of Nanomedicine , 2017, ACS nano.

[68]  Qiu Zhang,et al.  International Journal of Molecular Sciences the Current State of Nanoparticle-induced Macrophage Polarization and Reprogramming Research , 2022 .

[69]  E. Kitano,et al.  Studies of Pig Complement: Measurement of Pig CH50, ACH50, and Components. , 2016, Transplantation proceedings.

[70]  Bert Müller,et al.  Surprising lack of liposome-induced complement activation by artificial 1,3-diamidophospholipids in vitro. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[71]  Mohammad Ali Oghabian,et al.  An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[72]  J. Wood,et al.  Mast Cell: A Multi-Functional Master Cell , 2016, Front. Immunol..

[73]  S. Thiel,et al.  Complement activation, regulation, and molecular basis for complement‐related diseases , 2015, The EMBO journal.

[74]  F Locatelli,et al.  Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management , 2015, British journal of pharmacology.

[75]  S. Moghimi,et al.  Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[76]  S. Lai,et al.  Anti-PEG immunity: emergence, characteristics, and unaddressed questions. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[77]  R. Koenen,et al.  Microvesicles from platelets: novel drivers of vascular inflammation , 2015, Thrombosis and Haemostasis.

[78]  J. Szebeni,et al.  Hypersensitivity Reactions to Intravenous Lipid Emulsion in Swine: Relevance for Lipid Resuscitation Studies , 2014, Anesthesia and analgesia.

[79]  E. Conway,et al.  Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry. , 2014, ACS nano.

[80]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[81]  L. Cassard,et al.  Fcγ Receptors Inhibit Mouse and Human Basophil Activation , 2012, The Journal of Immunology.

[82]  R. Garrett,et al.  Archaeal viruses—novel, diverse and enigmatic , 2012, Science China Life Sciences.

[83]  T. Andresen,et al.  Particulate Systems for Targeting of Macrophages: Basic and Therapeutic Concepts , 2012, Journal of Innate Immunity.

[84]  Baljit Singh,et al.  Pulmonary intravascular macrophages and lung health: what are we missing? , 2012, American journal of physiology. Lung cellular and molecular physiology.

[85]  W. Hennink,et al.  Attaching the phage display-selected GLA peptide to liposomes: factors influencing target binding. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[86]  S. Thiel,et al.  The Role of Nanometer-Scaled Ligand Patterns in Polyvalent Binding by Large Mannan-Binding Lectin Oligomers , 2012, The Journal of Immunology.

[87]  J. Malmström,et al.  Stimulation of blood mononuclear cells with bacterial virulence factors leads to the release of pro‐coagulant and pro‐inflammatory microparticles , 2012, Cellular microbiology.

[88]  R. Veerhuis,et al.  Complement in the brain. , 2011, Molecular immunology.

[89]  John D. Lambris,et al.  Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine , 2011, The Journal of Immunology.

[90]  P. Bora,et al.  Polyethylene Glycol (PEG)-induced Mouse Model of Choroidal Neovascularization* , 2011, The Journal of Biological Chemistry.

[91]  Robert B Sim,et al.  Surface properties: Immune attack on nanoparticles. , 2011, Nature nanotechnology.

[92]  Eva Pebay-Peyroula,et al.  Proteins of the innate immune system crystallize on carbon nanotubes but are not activated. , 2011, ACS nano.

[93]  S Moein Moghimi,et al.  Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.

[94]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[95]  J. Kos,et al.  Procoagulant properties of bare and highly PEGylated vinyl-modified silica nanoparticles. , 2010, Nanomedicine.

[96]  D. Broide,et al.  Innate immunity. , 2010, The Journal of allergy and clinical immunology.

[97]  Thomas Vorup-Jensen,et al.  Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.

[98]  T. Mollnes,et al.  Pathway-specific complement activity in pigs evaluated with a human functional complement assay. , 2009, Molecular immunology.

[99]  S. Moghimi,et al.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. , 2008, Molecular immunology.

[100]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[101]  Takao Shimizu,et al.  Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. , 2008, Immunity.

[102]  H. Iwata,et al.  Complement activation on surfaces carrying amino groups. , 2008, Biomaterials.

[103]  J. Thurman,et al.  Candidate inhibitors of porcine complement. , 2007, Molecular immunology.

[104]  J. Buras,et al.  Mannose binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo , 2006, Immunobiology.

[105]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[106]  M. Bodó,et al.  Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. , 2006, American journal of physiology. Heart and circulatory physiology.

[107]  R. Dwek,et al.  Human Serum IgM Glycosylation , 2005, Journal of Biological Chemistry.

[108]  R. Müller,et al.  Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. , 2005, Biomaterials.

[109]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[110]  M. Daha,et al.  Opsonization with C1q and Mannose-Binding Lectin Targets Apoptotic Cells to Dendritic Cells1 , 2004, The Journal of Immunology.

[111]  C. Passirani,et al.  Long-Circulating Nanopartides Bearing Heparin or Dextran Covalently Bound to Poly(Methyl Methacrylate) , 1998, Pharmaceutical Research.

[112]  J. V. D. van der Meer,et al.  Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. , 2003, Blood.

[113]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  M. Olausson,et al.  Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. , 2003, The Journal of surgical research.

[115]  D. Relman,et al.  Archaea and Their Potential Role in Human Disease , 2003, Infection and Immunity.

[116]  F. Finkelman,et al.  Pathways of anaphylaxis in the mouse. , 2002, The Journal of allergy and clinical immunology.

[117]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[118]  G. Storm,et al.  Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. , 2001, Biochimica et biophysica acta.

[119]  H. Rus,et al.  Role of the C5b‐9 complement complex in cell cycle and apoptosis , 2001, Immunological reviews.

[120]  H. Lutz,et al.  The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .

[121]  C. Oussoren,et al.  Preclinical and Clinical Evidence for Efficient Opsonization of Poly(Ethyleneglycol)-Liposomes , 2000 .

[122]  N. Staub,et al.  Intravascular macrophage depletion attenuates endotoxin lung injury in anesthetized sheep. , 1999, Journal of applied physiology.

[123]  J. Brain,et al.  Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[124]  A. Schmaier,et al.  Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. , 1997, Blood.

[125]  P Couvreur,et al.  Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. , 1997, Life sciences.

[126]  R. Müller,et al.  Identification of plasma proteins facilitated by enrichment on particulate surfaces: Analysis by two‐dimensional electrophoresis and N‐terminal microsequencing , 1997, Electrophoresis.

[127]  T. Fujita,et al.  A Novel Human Serum Lectin with Collagen- and Fibrinogen-like Domains That Functions as an Opsonin (*) , 1996, The Journal of Biological Chemistry.

[128]  P. Constantinides.  Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. , 1995, Circulation.

[129]  J. Freyssinet,et al.  Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. , 1994, Journal of immunology.

[130]  D. Devine,et al.  Liposome-complement interactions in rat serum: implications for liposome survival studies. , 1994, Biochimica et biophysica acta.

[131]  S. Davis,et al.  Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan‐stimulated rats , 1993, Journal of leukocyte biology.

[132]  O. Ogunremi,et al.  A non-hemolytic assay for the activation of the alternative pathway of bovine complement. , 1993, Veterinary immunology and immunopathology.

[133]  J. H. Jansen,et al.  Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). , 1993, The American journal of pathology.

[134]  L. Illum,et al.  In vivo evaluation of protein adsorption to sterically stabilised colloidal carriers. , 1993, Journal of biomedical materials research.

[135]  E. Kremmer,et al.  Differences in the activity of the alternative pathway of complement in BALB/c and C57Bl/6 mice. , 1993, Experimental and clinical immunogenetics.

[136]  J. Westcott,et al.  Development of pulmonary intravascular macrophage function in newborn lambs. , 1992, Journal of applied physiology.

[137]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[138]  P. Cullis,et al.  Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. , 1991, Biochimica et biophysica acta.

[139]  D. Devine,et al.  The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. , 1991, Journal of immunology.

[140]  B. Perussia,et al.  FcγRIII (CD16) on human macrophages is a functional product of the FcγRIII‐2 gene , 1991 .

[141]  M. J. Mattes,et al.  Mouse strains with typical mammalian levels of complement activity. , 1989, Journal of immunological methods.

[142]  D. Dehring,et al.  Intravascular macrophages in pulmonary capillaries of humans. , 1989, The American review of respiratory disease.

[143]  F. Bonte,et al.  Interactions of polymerizable phosphatidylcholine vesicles with blood components: relevance to biocompatibility. , 1987, Biochimica et biophysica acta.

[144]  F. Bonte,et al.  Interactions of liposomes with serum proteins. , 1986, Chemistry and physics of lipids.

[145]  A. Aderem,et al.  Ligated complement receptors do not activate the arachidonic acid cascade in resident peritoneal macrophages , 1985, The Journal of experimental medicine.

[146]  T. Fujita,et al.  Sexual dimorphism of the fifth component of mouse complement , 1984, The Journal of experimental medicine.

[147]  S. Wright,et al.  Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes , 1983, The Journal of experimental medicine.

[148]  R. Discipio.  The activation of the alternative pathway C3 convertase by human plasma kallikrein. , 1982, Immunology.

[149]  W. D. Linscott,et al.  The bovine complement system. , 1981, Advances in experimental medicine and biology.

[150]  J. J. Imarisio.  Liver scan showing intense lung uptake in neoplasia and infection. , 1975, Journal of Nuclear Medicine.

[151]  J. Keyes,et al.  An evaluation of lung uptake of colloid during liver imaging. , 1973, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[152]  O. Götze,et al.  Release of trapped marker from liposomes by the action of purified complement components. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[153]  C. Alving,et al.  Antibody binding and complement fixation by a liposomal model membrane. , 1969, Biochemistry.

[154]  S. Kinsky,et al.  Immune response of a liposomal model membrane. , 1968, Proceedings of the National Academy of Sciences of the United States of America.